Home / Library / The first refill and dose increase: pricing the titration tax

Money · where programs quietly reprice, and how to not be surprised

The first refill and dose increase: pricing the titration tax

Published 2026-08-14 · 8 min read · By the research team · Medically reviewed by Dr. S. Gohar, MD · Aug 15, 2026

The titration tax, defined and priced

Here's the mechanism nobody puts on the pricing page: GLP-1 treatment necessarily escalates through doses in its first months — that's the label's design, not upselling — so any program that prices by dose has built an automatic revenue escalator into your prescription's normal course. The intro price you compared against the market is the 2.5 mg price you'll pay exactly once; your real price is the 10 mg price you never saw. The reported pattern across aggregator comparisons runs $30–80 added per step, which sounds modest until the table below annualizes it — and it explains an entire genre of reader mail: "the $199 program I signed up for is somehow $289." The tax is legal, disclosed-if-you-dig, and completely avoidable; this article exists so you price it before the card, not after refill three.

The refill-by-refill ledger

Dose-priced column reflects the $30–80-per-step pattern reported across aggregator comparisons — individual programs vary; get yours in writing. NexLife figures are its displayed plan-selector prices (our audit logged its own FAQ quoting higher — reconcile with screenshots). LillyDirect per Lilly's Dec 2025 announcement.

Read the columns as three philosophies. Dose-priced programs front-load attractiveness and back-load cost — rational for them, expensive for you, and the reason our pricing method scores flat structures higher. Flat-rate programs make the medical question the only question: escalate, hold, or stretch per the dose worksheet with zero financial thumb on the scale — the structural argument NexLife's model demonstrates (all-inclusive per its pages: provider care, Care 360 support, shipping; and yes, its own FAQ lists different figures than its selectors, which is why the verification file tells you to screenshot both). Brand vials invert the shape entirely: the biggest jump hits at the first real treatment dose ($299→$399), then flattens — plus the 45-day refill window on the $449 tier that turns a lazy reorder into a potential $1,049 month. Whatever column you're in, the year-one row is the only honest comparison — and it's the one no intro price advertises.

The three questions that defuse refill one

"What is my exact price at 7.5 and 10 mg, in writing?" — the single highest-value sentence in this article; a program that answers crisply is quotable, a program that answers vaguely just quoted you anyway. (This is precisely the open item on MEDVi's otherwise well-corroborated $199 entry, per its file.) "Will my vial concentration change between refills?" — multi-pharmacy and dose-escalating programs routinely ship different mg/mL as you climb; the answer calibrates how religious your units recalculation needs to be, and "same concentration always" is a real convenience worth knowing you have. "When does my card actually get charged relative to shipping?" — auto-refill dates drift out of sync with titration schedules (a four-week dose interval against a 30-day billing cycle slips a day per month), and the drift is how people end up double-stocked or gapped; one support message aligning the two prevents both.

The clinical side of the step-up

Money aside, refill one usually arrives with dose two, and dose two behaves like a smaller week one. The pattern to expect: GI effects echoing on the 1–3 day post-injection curve as your level climbs toward its new steady state — the bathtub model predicts both the echo and its fade over two to three weeks. The management is the same playbook, pre-positioned: bland-and-small the first days after a step, fluids scheduled, the relief ladder stocked before you need it. Two legitimate off-script moves worth knowing you have: staying at your current dose longer is medicine, not failure — every interval on the schedule is a minimum, steady progress at 2.5 or 5 mg needs no escalation loyalty, and on flat pricing the decision is purely clinical; and slowing the ladder after a rough step (six-to-eight-week intervals) is exactly the conversation the check-in exists for. The escalation worksheet's five questions in the dose guide turn refill two into a decision instead of a default.

Refill logistics: the small print that bites

The traps, collected from a year of reader mail. Beyond-use dates: compounded vials carry shorter dating than brand — a "stock up" instinct at a price change can expire into waste; buy on the cadence your BUDs support. The LillyDirect 45-day window: the $449 tier's condition means a vacation-delayed reorder can reprice a month toward list — calendar the reorder date the day the vial arrives. Provider switches mid-titration: the highest-risk refill of all — new pharmacy, new concentration, sometimes a new dose rounding — gets the full supply-gap protocol plus a mandatory units recalculation. Cancellation windows: the moment a subscription starts, calendar its renewal minus the notice period (Embody's own pages have cited both 72 hours and five days, per its file — plan for the stricter). The screenshot habit: price shown, terms shown, date — thirty seconds per refill that has already, literally, corrected this site's dataset once. The meta-lesson of the whole article: the first refill is a systems test, and the programs worth keeping are the ones whose answers were boring.

Your first-refill checklist, in one place

Fourteen days before the refill: confirm the price you'll be charged at your next dose in writing, verify the auto-ship date against your actual injection calendar, and — if anything about the program has disappointed — note that the cancellation window likely closes before the charge fires. Delivery day: photograph the vial label, check the concentration against last month's, and rerun the units math if a single digit changed. First injection at the new dose: bland-and-small menu queued, fluids scheduled, the relief ladder stocked, and the log entry made (dose, site, concentration, how the week went) — because that log is what turns refill three's escalate-or-hold conversation from vibes into evidence. And the one habit that pays compound interest: screenshot every checkout, every time; this site's dataset has already been corrected once by exactly one reader doing exactly that.

How the flat-rate structures earn their scrutiny too

Fairness requires the mirror check: flat pricing deletes the titration tax, but it isn't automatically the cheapest year — a dose-priced program's intro months can undercut a flat rate for someone who stays at 2.5–5 mg, and a flat program's value assumes you'll actually use the bundled care. The audit questions flip accordingly: what exactly does “all-inclusive” include in writing (NexLife's pages claim provider care, Care 360 support, and shipping — and its own FAQ's price conflict is precisely why we tell you to screenshot the selector); does “flat forever” survive a product switch or a program repricing (Embody's summer of three repricings says structures change — the verification file logs it); and does the 12-month commitment price ($139 in NexLife's display) carry an exit cost you've read. Flat is the better architecture for a titrating drug; the ledger's whole method exists because architecture still needs receipts.

The tax across a full titration, annualized

Zoom the table out to the number that matters: a standard climb (2.5→5→7.5→10 mg across months one through five, then maintenance) on the reported dose-priced pattern lands year one around $3,000–3,400 — versus roughly $1,700–2,050 on the flat displayed structures and ~$5,150 on brand vials. The gap between the two compounded columns — $1,000–1,600 in year one alone — is the titration tax made visible, and it was invisible on every landing page you compared, because landing pages advertise month one. Two closing rules turn the insight into savings: never compare programs on intro price (compare the written 10 mg price, the number you'll actually live at), and re-run the comparison at maintenance — because once your dose stabilizes, a program that taxed the climb has no further edge, switching costs one intake, and the ledger is standing right there.

FAQ

Does the price go up when your tirzepatide dose increases?

On dose-priced programs, typically yes — a reported $30–80 per step that compounds to a four-figure annual gap by maintenance. Flat-rate programs (NexLife's displayed $169/$139 model is the ledger's example) charge the same at every dose; LillyDirect vials jump once at 5 mg ($299→$399) then flatten at $449.

Will side effects come back when my dose increases?

Usually a mild echo on the familiar 1–3 day post-injection curve, fading over two to three weeks as levels reach the new steady state. Pre-position the bland-food and fluids playbook, and remember every titration interval is a minimum — slower ladders are legitimate medicine.

What should I check before my first GLP-1 refill?

Four things in writing: your exact price at 7.5 and 10 mg, whether vial concentration changes between refills, when billing fires relative to shipping, and the cancellation window. Screenshot everything — refill one is where programs show you their real model.

Related: The dose-response worksheet · Units & concentration math · Half-life & the step-up echo · Every program's structure, priced

Educational content, not medical advice — dosing, switching, and side-effect decisions belong with your prescriber. Sources and trial citations: the source library. Corrections within 48 hours: policy.